<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00978224</url>
  </required_header>
  <id_info>
    <org_study_id>CAT-0907-CU</org_study_id>
    <nct_id>NCT00978224</nct_id>
  </id_info>
  <brief_title>Viusid Administration in Subjects With Chronic Inflammatory Syndrome Under Hemodialysis Treatment</brief_title>
  <official_title>Efficacy of Viusid Administration in Subjects With Chronic Inflammatory Syndrome Under Hemodialysis Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Catalysis SL</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Catalysis SL</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to determine whether Viusid administration improves malnutrition,
      atherosclerosis, erythropoietin response and the frequency of infection episodes in subjects
      with Chronic Inflammatory Syndrome under hemodialysis treatment. The duration of this
      double-blind placebo controlled phase 3 clinical trial will be 60 weeks. All patients
      enrolled in the study will be receiving the standard treatment for Chronic Inflammatory
      Syndrome including hemodialysis and administration of a hypercaloric and hyperproteic diet.
      Efficacy assessment will be carried out 12 weeks after the end of Viusid or placebo
      treatment.
    </textblock>
  </brief_summary>
  <overall_status>Suspended</overall_status>
  <why_stopped>
    Decision of the investigator
  </why_stopped>
  <start_date>October 2009</start_date>
  <completion_date type="Anticipated">September 2011</completion_date>
  <primary_completion_date type="Anticipated">September 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Body mass index (BMI) at week 72 (end of the treatment)</measure>
    <time_frame>72 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Carotidal Doppler at week 72 (end of the treatment)</measure>
    <time_frame>72 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>C reactive protein at weeks 72 (end of the treatment)</measure>
    <time_frame>72 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Hemoglobin at week 72 (end of the treatment)</measure>
    <time_frame>72 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cholesterol at week 72</measure>
    <time_frame>72 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Triglycerides at week 72</measure>
    <time_frame>72 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of infection episodes at week 72</measure>
    <time_frame>72 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Creatinine at week 72</measure>
    <time_frame>72 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Uric acid at week 72</measure>
    <time_frame>72 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glutamic-pyruvic transaminase (GPT)at week 72</measure>
    <time_frame>72 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glutamic-oxaloacetic transaminase (GOT)at week 72</measure>
    <time_frame>72 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood glucose concentrations at week 72</measure>
    <time_frame>72 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gasometry at week 72</measure>
    <time_frame>72 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse effects at week 72</measure>
    <time_frame>72 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Albumin at week 72</measure>
    <time_frame>72 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>KTV at week 72</measure>
    <time_frame>72 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phosphocalcic metabolism at week 72</measure>
    <time_frame>72 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hematocrit at week 72</measure>
    <time_frame>72 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">152</enrollment>
  <condition>Chronic Inflammatory Syndrome</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Viusid in combination with standard treatment for Chronic Inflammatory Syndrome including hemodialysis and the administration of a hypercaloric and hyperproteic diet</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo in combination with standard treatment for Chronic Inflammatory Syndrome including hemodialysis and the administration of a hypercaloric and hyperproteic diet</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Viusid</intervention_name>
    <description>3 Viusid bags (Orally administered) per day, for 60 weeks</description>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>3 Placebo bags (Orally administered) per day, for 60 weeks.</description>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects with chronic terminal nephropathy under hemodialysis treatment for at least 3
             months

          -  Signed informed consent

        Exclusion Criteria:

          -  Patients with chronic terminal nephropathy previously treated with peritoneal dialysis

          -  Receptors of a renal graft

          -  Patients with malignant neoplastic conditions

          -  Pregnant women
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mirna Atiés Sánchez, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institute of Nephrology &quot;Dr. Abelardo Buch López&quot;</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Institute of Nephrology &quot;Dr. Abelardo Buch López&quot;</name>
      <address>
        <city>Havana</city>
        <zip>10400</zip>
        <country>Cuba</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Cuba</country>
  </location_countries>
  <verification_date>July 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 15, 2009</study_first_submitted>
  <study_first_submitted_qc>September 15, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 16, 2009</study_first_posted>
  <last_update_submitted>July 6, 2010</last_update_submitted>
  <last_update_submitted_qc>July 6, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 7, 2010</last_update_posted>
  <responsible_party>
    <name_title>Mirna Atiés Sánchez</name_title>
    <organization>Institute of Nephrology</organization>
  </responsible_party>
  <keyword>dietary supplement</keyword>
  <keyword>hemodialysis</keyword>
  <keyword>Chronic Inflammatory Syndrome</keyword>
  <keyword>Viusid</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

